Xi stresses common development, win-win cooperation
BEIJING, Jan. 17, 2022 /PRNewswire/ -- A report from chinadaily.com.cn:
President Xi Jinping delivered a speech at a virtual event of the World Economic Forum on Monday amid anticipation of China's contribution to global economic recovery. This was his third time speaking at the forum as a head of state.
Here are some highlights:
On China's economy
- We have every confidence in the future of China's economy
- China's development gains will benefit all its people in a more substantial and equitable way
- China should never grow the economy at the cost of resource depletion and environmental degradation, nor should the country sacrifice growth to protect the environment
On global recovery
- World should follow logic of historical progress, ride tide of times
- No 'counter-currents' can stop trend of economic globalization
- Different countries and civilizations may prosper together on the basis of respect for each other, and seek common ground and win-win outcomes by setting aside differences
We need to explore new drivers of economic growth to promote steady and solid progress in global economic recovery
On COVID-19
- Countries need to strengthen international cooperation against COVID-19, carry out active cooperation on research and development of medicines
- Of particular importance is to fully leverage vaccines as a powerful weapon, ensure their equitable distribution
- China will provide another 1 billion COVID-19 vaccine doses to African countries, and donate 150 million doses to ASEAN countries
On Winter Games
China will present streamlined, safe, and splendid Winter Games
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...